15 Amyloidosis Clinical Trials in Boston, MA (2026)

Q: How do I join a clinical trial in Boston?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Boston research site will contact you.

Recruiting Amyloidosis Studies in Boston

NCT07358078Recruiting

DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting

The purpose of this study is to: * Describe the clinical characteristics of adult patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM) treated with vutrisiran in routine cli...

Boston, MA2,000 participantsAlnylam Pharmaceuticals

View Study Details

NCT06465810Recruiting

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patter...

Boston, MA1,850 participantsAstraZeneca

View Study Details

NCT04561518Recruiting

ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

The purpose of this study is to: * Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients * Characterize the safety and...

Boston, MA1,500 participantsAlnylam Pharmaceuticals

View Study Details

NCT05577819Recruiting

Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF

Recent studies have shown that transthyretin amyloidosis (ATTR) can sometimes cause a type of heart failure where the pumping function of the heart is normal, also known as Heart Failure with Preserve...

Boston, MANA515 participantsMassachusetts General Hospital

View Study Details

NCT07690436Recruiting

Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM

This multicenter pilot study will enroll adult participants with a confirmed clinical diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) and heart failure (HF) controls with documentation wit...

Boston, MA500 participantsAstraZeneca

View Study Details

NCT06292780Recruiting

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

This study is researching an experimental drug called linvoseltamab ("study drug"). This study is focused on patients who have AL amyloidosis that has returned or have failed other therapies and need...

Boston, MAPHASE1220 participantsRegeneron Pharmaceuticals

View Study Details

NCT02641145Recruiting

Molecular Imaging of Primary Amyloid Cardiomyopathy

Cardiac amyloidosis is a major cause of early treatment-related death and poor overall survival in individuals with systemic light chain amyloidosis. This project will develop a novel approach to visu...

Boston, MANA171 participantsBrigham and Women's Hospital

View Study Details

NCT07223203Recruiting

TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy

The purpose of this study is to: * Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment, quality of life, nutritional status, disability, a...

Boston, MAPHASE3125 participantsAlnylam Pharmaceuticals

View Study Details

NCT07081646Recruiting

A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.

Open-label Phase 1b/2 study with primary objective of this study is to evaluate the safety, tolerability and efficacy of AZD0120 in participants with light chain (AL) amyloidosis....

Boston, MAPHASE191 participantsAlexion Pharmaceuticals, Inc.

View Study Details

NCT06158854Recruiting

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion

Immunoglobulin light chain (AL) amyloidosis is the most common form of systemic amyloidosis. AL amyloidosis has many root causes and is characterized by the overproduction of AL that are secreted by c...

Boston, MAPHASE176 participantsAbbVie

View Study Details

NCT04667494Recruiting

Ultrasound Therapy In Cardiac Amyloidosis

This is a prospective pilot clinical study of subjects with cardiac amyloidosis and control subjects without amyloidosis where we plan to evaluate changes in myocardial blood flow, systolic and diasto...

Boston, MAPHASE470 participantsBrigham and Women's Hospital

View Study Details

NCT06569147Recruiting

Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis

This study will evaluate the safety, tolerability and efficacy of elranatamab in patients with relapsed or refractory AL amyloidosis....

Boston, MAPHASE149 participantsBrigham and Women's Hospital

View Study Details

NCT05797857Recruiting

Exercise Training in Transthyretin Cardiac Amyloidosis

Transthyretin cardiac amyloidosis causes debilitating heart failure in older adults. The proposed research will develop a personalized exercise training program to improve functional capacity in patie...

Boston, MANA40 participantsBrigham and Women's Hospital

View Study Details

NCT07110844Recruiting

Teclistamab-Daratumumab in AL Amyloidosis

The purpose of this study is to investigate whether teclistamab-daratumumab combination is effective and safe in AL amyloidosis. The study treatment is divided into cycles (C) and each cycle is 28 da...

Boston, MAPHASE225 participantsSuzanne Lentzsch, MD

View Study Details

NCT07560306Recruiting

[64Cu]FBP8 PET for Early Detection of Intracardiac Thrombus in Amyloid Cardiomyopathy

The primary goal of this pilot study is to determine whether \[64Cu\]FBP8, a novel fibrin-binding positron emission tomography (PET) probe, can identify intracardiac thrombi when paired with simultane...

Boston, MAPHASE320 participantsBrigham and Women's Hospital

View Study Details

About Amyloidosis Clinical Trials in Boston

Amyloidosis is a group of diseases in which abnormal proteins (amyloids) build up in organs and tissues, impairing their function. Types include AL, AA, and ATTR amyloidosis. Treatment depends on the type and may include chemotherapy, organ transplant, or targeted therapies.

There are currently 15 amyloidosis clinical trials recruiting participants in Boston, MA. These studies are seeking a combined 7,252 participants. Research is being sponsored by Alnylam Pharmaceuticals, AstraZeneca, Massachusetts General Hospital and 5 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Amyloidosis Clinical Trials in Boston — FAQ

Are there amyloidosis clinical trials in Boston?

Yes, there are 15 amyloidosis clinical trials currently recruiting in Boston, MA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Boston?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Boston research site will contact you about next steps.

Are clinical trials in Boston free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Boston studies also compensate for your time and travel.

What amyloidosis treatments are being tested?

The 15 active trials in Boston are testing new therapies including novel drugs, biologics, and treatment approaches for amyloidosis.

Data updated October 12, 2026 from ClinicalTrials.gov